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Abstract: Heparin has been conjugated to Fe3O4, Co3O4, and NiO nanoparticles (NPs) 
through electrostatic interactions, producing colloidal suspensions of hybrid metal oxide 
heparin NPs that are stable in water. Negative zeta potentials and retention of heparin’s 
ability to capture toluidine blue indicate that heparin’s negative charges are exposed on the 
surface of the coated NPs. IR results confirmed the formation of nanohybrids as did NMR 
experiments, which were also interpreted on the basis of toluidine blue tests. Transmission 
electron microscopy results revealed that the heparin coating does not modify the shape or 
dimension of the NPs. Dynamic light scattering and negative zeta potential measurements 
confirmed that heparin surface functionalisation is an effective strategy to prevent   
NP aggregation. 
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1. Introduction 
Nanoparticles (NPs) can act as core materials, providing a useful platform for surface 
functionalisation, for applications in biomedicine, catalysis, and electronic devices [1]. The use of 
composite NPs in analytical chemistry has also been specifically reviewed [2]. 
Since the early 2000s, much effort has been made to combine the intrinsic properties of 
biomolecules with the unusual and size-dependent material properties of NPs [3]. When integrated 
with biomolecules, NPs with metallic, metal oxide (MO), semiconductor, or silica cores have been 
used in a wide range of applications in biology and medicine [4,5]. Moreover, Au NPs are emerging as 
therapeutics in their own right, with the capability of modulating cellular processes based on their 
surface functionality [6].  
A recent review summarised the synthesis and biofunctionalisation of inorganic metal, 
semiconductor and magnetic nanoparticles for applications in many areas of biomedicine, from 
diagnostics to the treatment of diseases [7]. The rapid detection of Hendra virus using magnetic 
particles and quantum dots has also been reported recently [8]. 
A special issue on theranostic nanomedicine [9] listed twenty-eight accounts of various inorganic 
NPs, lipid aggregates and synthetic polymer systems, detailing the physicochemical properties of these 
biocompatible NP platforms. Unfortunately, however, the very active research on new nanomaterials 
that are potentially useful in medicine has not been counterbalanced by an adequate knowledge of their 
pharmacokinetics and toxicity [10]. 
In this study, we describe how to engineer transition metal oxide NPs of the three ferromagnetic 
elements, Fe, Co and Ni (i.e., Fe3O4, Co3O4, and NiO) with heparin, with the aim of merging the 
properties of the individual components. 
The natural occurring anticoagulant heparin is a heterogeneous, polydisperse, highly sulphated 
glycosaminoglycan composed of 1→4 linked disaccharide repeating units, which consist of an   
α-D-glucosamine (A) and a hexuronic acid, α-L-iduronic (I) or β-D-glucuronic (G) acid unit, with   
O-sulphate groups at different positions on the disaccharide unit [11]. The most frequently occurring 
repeating disaccharide sequence is α-L-iduronic acid-2-O-sulphate-α-D-glucosamine-N,6-disulphate 
(I2S-ANS,6S), which represents the highly sulphated segment of heparin, whereas under-sulphated 
sequences contain ANAc (α-D-glucosamine-N-acetyl) and non-sulphated, I and G. Heparin and low 
molecular weight heparin have both been recognised as anti-angiogenic agents and vectors that are 
able to bind proteins that are involved and over-expressed in the tumour microenvironment [12,13]. 
Some chemically modified heparin species have also been reported to exert a beneficial effect in 
cancer patients, regardless of the mode of action [14]. 
Iron oxide (Fe3O4) and Fe-based alloy NPs, such as iron-cobalt (FeCo), provide a unique 
nanoplatform for theranostic applications because of their biocompatibility, their responses to external 
magnetic fields, and their sizes, which are comparable to those of functional biomolecules [15]. Int. J. Mol. Sci. 2013, 14  13465 
 
 
Furthermore, because of the ease of fabrication and their approved clinical usage, Fe3O4 NPs with 
controlled sizes and controlled surface chemistry have been studied extensively for Magnetic Resonance 
Imaging (MRI) and Magnetic Fluid Hyperthermia (MFH) applications [16,17]. Superparamagnetic 
Iron Oxide NPs (SPION) were recently introduced for MRI, drug delivery, drug-targeting, and 
hyperthermia through intra- or extra-venous injection [18–20]. Surface engineering of iron oxide NPs 
has been widely studied for targeted cancer therapy [21]. 
As reported by Klostergaard [22], based on the advanced stage of preclinical human tumour 
xenograft studies with Fe-based magnetically responsive nanoparticles, there is great confidence that 
the broader requirements for moving forward to clinical applicability will be met. Therefore, our 
interest focuses on Fe3O4. 
The same paper also investigated Co3O4 and NiO and discussed their toxicity and the risk of their 
use. Although we are conscious of the toxicity aspects of administering NPs [23–25], the many 
applications of Co3O4 and NiO nanohybrids prompted us to prepare and characterise metal   
oxide-heparin nanohybrids. The presence of cobalt and nickel within biofunctional magnetic NPs for 
the manipulation of proteins and cells supported our challenge [26]. 
On the nanoscale, Co3O4 exhibits magnetic, optical, field emission and electrochemical properties 
that are attractive in device applications [27–29]. Cobalt ferrite (mixed cobalt iron oxide) NP formation 
was studied in the presence of a synthetic polypeptide, and coating this material with histidine induced 
cellular biocompatibility [30,31]. NiO can form part of electrochemical devices, in which Ni ions are 
also used as an agent for chelating biomolecules [32,33]. A nonenzymatic glucose sensor based on a 
nickel(II)oxide/ordered mesoporous carbon-modified glassy carbon electrode has also been recently 
reported [34]. 
Concerning polysaccharides, dextran-coated iron oxide NPs have been proposed as a versatile 
platform for targeted molecular imaging, molecular diagnostics, and therapy [35]. 
In addition, Chertok et al. [36] argued clearly how and why iron oxide NPs could be promising drug 
delivery vehicles for MRI-monitored magnetic targeting of brain tumours. Currently, we focus on a 
heparin skeleton with the aim of taking advantage of the multiple roles that heparin can play. In 
particular, the heparin coating could specifically direct iron oxide NPs to a tumour mass 
microenvironment, where their paramagnetic properties can be simultaneously exploited for MRI and 
hyperthermia, and could exert non-conventional drug activity inside the tumour cells because of the 
ability of the NPs to cross the cell membrane. 
2. Results and Discussion 
Complex nanostructures of inorganic elements coated by polymers have been covalently linked to 
heparin through spacers [37,38]. Covalent linkages between nanomaterials and biomolecules often lead 
to a reduction in the biological activity of the biomolecules once attached to the nanoparticle’s   
surface [39,40]. Thus, non-covalent bioconjugation techniques, based on hydrogen bonding, electrostatic 
interactions and antibody–antigen interactions, are often advantageous for the biofunctionalisation of 
nanomaterials [41,42]. 
In this work, the creation of MO@heparin NPs was achieved via the electrostatic attachment of 
heparin to the surface of NPs. Because heparin was not manipulated, its structure in MO@heparin NPs Int. J. Mol. Sci. 2013, 14  13466 
 
 
was reasonably preserved. Another example of non-covalent heparin bioconjugation on   
poly-L-lysine-coated iron oxide NPs, [43] has been published, to which we refer in detail in   
the discussion. 
MO@heparin NPs were prepared, as detailed in the experimental section, using a one-pot coating 
reaction at room temperature; by this method, the formation of any by-products was avoided, and the 
excess of heparin as a starting material could be easily recovered and recycled. The washing procedure 
with diethyl ether removed water and residual non-linked heparin and provided the final MO@heparin 
NPs which were characterised using a colorimetric assay, FT-IR spectroscopy, DLS and zeta potential 
measurements, TEM and 
1H NMR spectroscopy. 
The NP weight increase observed after coating (Table 1) indicates the order of magnitude of the 
heparin:metal ratio.  
Table 1. Gravimetric and colorimetric data for heparin coating. 
NP  Starting NP (mg)  MO@heparin weight increase (mg)  TB assay heparin coating (mg) 
Co3O4 100  11  10–19 
NiO 100  19  10–22 
Fe3O4 100  5  10–15 
Gravimetric data can sometimes be underestimated because of the difficulty of recovering and 
handling the wet material. Therefore, the toluidine blue (TB) colorimetric method, used to assay the 
heparin content in immobilised heparin preparations, was tested on heparin-coated NPs [44]. This 
method is based on the metachromatic effect induced by heparin sulphate groups on TB in the 400 to 
650 nm wavelength range. All of the coated NPs were effective at inducing the metachromatic effect. 
The same experiment performed with the addition of bare NPs did not influence the TB absorbance. 
Figure 1 reveals the spectral characteristics of TB supernatant depletion upon addition of 
Fe3O4@heparin NP.  
Figure 1. UV-Vis absorption spectra of TB before (red) and after (blue) the addition of 
Fe3O4@heparin NP. The comparison highlights the depletion of TB in the supernatant upon the 
addition of Fe3O4@heparin NP. 
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Based on a standard curve reported in the experimental section, the amount of coating for 100 mg of 
NPs was measured (Table 1). 
Co3O4@heparin and NiO@heparin NPs were repeatedly analysed by TB assay. The data range 
reported in Table 1 fit well with the gravimetric data. The Fe3O4@heparin NP colorimetric data range 
appears a little narrower and the gravimetric datum seems underestimated. Fe3O4@heparin NP was 
prepared several times and their TB assay appears quite reproducible.  
By averaging the gravimetric and colorimetric data in Table 1, the amount of immobilised heparin 
can be reasonably evaluated to be in the range of 10%–20% (w:w) when heparin is in large excess. 
Decreasing the amount of heparin during the synthesis, as for Fe3O4@heparin NPs (Table 2), results in 
a lower functionalisation of Fe3O4. 
Table 2. Heparin coating of Fe3O4@heparin NP prepared under different heparin/Fe3O4 
ratio, determined by the colorimetric assay. 
Starting Heparin (g/mL)  Starting NP (g/mL)  Heparin/NP w/w  TB assay heparin coating (mg) 
0.033 0.003  11  15 
0.028 0.010  2.8  9 
0.022 0.016  1.4  2 
For each MO@heparin NP preparation, the presence of heparin was detected by FT-IR spectra.  
FT-IR spectra of NPs before and after modification with heparin are presented in Figures 2–4, along 
with the reference spectra for heparin. 
Figure 2. FT-IR spectra of Fe3O4@heparin NP compared with those of heparin and bare 
Fe3O4 NP. 
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Figure 3. FT-IR spectra of Co3O4@heparin NP compared with those of heparin and bare 
Co3O4 NP. 
 
In the NP spectra, two bands characteristic of adsorbed water (1631 cm
−1) and carbonate stretching 
(1384 cm
−1) are observed, resulting from the exposure of the samples to air [45,46]. A broad OH 
stretching band of hydrogen-bonded water is observed at 3438 cm
−1. The two broad bands at 1631 cm
−1 
from moisture and at 1125 cm
−1 exhibited by Fe3O4 are quite similar to those observed for the 
unmodified iron oxide sample by Khurshid [43]. In the range 900–400 cm
−1, the IR bands of solids are 
usually assigned to the vibration of ions in the crystal lattice [47]. The spectra of pure solids consisted 
of two bands in the range 592–499 cm
−1 for Fe3O4 and in the range 667–568 cm
−1 for Co3O4, whereas 
one band appeared at approximately 438 cm
−1 for NiO.  
Figure 4. FT-IR spectra of NiO@heparin NP compared with those of heparin and bare 
NiO NP. 
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In the FT-IR spectra of the MO@heparins NPs, the main bands of heparin are clearly 
distinguishable. After coating the particles with heparin, the sulphate bands of heparin at   
1240–1260 cm
−1 and 1019 cm
−1 were clearly visible, confirming the presence of heparin on 
MO@heparin NPs. Some bands in the range 1550–1400 cm
−1 can be assigned to CO2
− stretching.  
In MO@heparin NPs, the sulphonamide –NHSO3
− stretching bands at 891 cm
−1 are of lower   
intensity than in heparin, in perfect agreement with the spectra of heparin-coated Fe3O4 described by 
Khurshid [43]. 
The purple centrifuged MO@heparin-TB adducts were dried under vacuum and were also 
investigated using IR. The FT-IR spectra in Figure 5 demonstrate that the stretching frequencies of the 
TB functional group -N
+(CH3)2 shifted from 1382.84 cm
−1 and 1322.77 cm
−1 (free TB) to   
1457–1460 cm
−1 and 1371–1377 cm
−1 (TB interacting with heparin). These shifts are consistent with 
the structure of the MO@heparin-TB adducts, in which heparin’s negative charges are associated with 
TB’s positive quaternary amino group -N
+(CH3)2. Figure 6 presents a comparison between TB and the 
Fe3O4@heparin-TB adduct. The bare NPs that were added to the TB solution were black in color when 
recovered and did not yield significant IR spectra. 
Figure 5. FT-IR spectra of the Fe3O4@heparin-TB adduct (blue) and TB (red). 
 
Figure 6. Turbidity effect for MO@heparin NP and bare NP suspensions. 
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Figure 6 reports light absorption at 600 nm for the coated and bare NPs suspended in   
distilled water (1 mg/mL). The coated NP suspensions reach higher absorbance values   
(NiO@heparin < Fe3O4@heparin < Co3O4@heparin). This effect is permanent, as the coated NP 
suspensions remained unaltered. 
Dynamic light scattering (DLS) experiments produced further information about the supernatant of 
the MO@heparin NPs water suspensions. For samples described in Table 1, more than 50% of 
NiO@heparin NP preparation and Co3O4@heparin NP preparation was solubilised, whereas only 
approximately 20% of the Fe3O4@heparin NP preparation was solubilised.  
Table 3 reports the Z-Average (Z-A) value as the mean value of the hydrodynamic radius of 
suspended MO@heparin NPs and the PolyDispersity Index (PDI) which is a measure of the width of 
the NP size distribution. The Z-A for all three MO@heparin NPs appear to be quite similar, with PDI 
values <0.3; in contrast, DLS experiments on bare NPs showed a dispersion of larger NPs that rapidly 
aggregate, yielding a high PDI (data not shown). The lower aggregation of MO@heparin NPs is a 
result of the presence of the heparin coating. The behaviour of a suspension of Fe3O4@heparin NP in 
water was followed for 24 h. The Z-A tended to a constant value in 12 h (Figure 7).  
Table 3. Z-A and PDI of MO@heparin NPs. 
MO@heparin Z-A  (nm)  PDI 
Co3O4@heparin 103  0.17 
Fe3O4@heparin 92  0.17 
NiO@heparin 93  0.23 
Figure 7. Kinetic behaviour of Fe3O4@heparin NP in H2O at 37 °C. 
 
The ζ measurements of bare NPs and of coated NPs described in Table 1 were performed at a 
concentration of 25 μg/mL in water and recorded at 25 °C, see Table 4. The heparin coating resulted in 
MO@heparin NPs having a highly negative surface charge, consistent with the colorimetric assays in 
the presence of TB. The same trend has been observed for non-covalent bioconjugation of heparin to 
poly-L-lysine-coated iron oxide NPs [43]. 
Table 4. Bare and coated NP ζ. 
NP  ζ (mV)  MO@heparin  ζ (mV) 
Co3O4  −31 Co3O4@heparin  −70 
Fe3O4  −14 Fe3O4@heparin  −61 
NiO +19  NiO@heparin  −47 
50
60
70
80
90
100
110
0 250 500 750 1000 1250 1500
Time (min)
Z
-
A
 
(
n
m
)Int. J. Mol. Sci. 2013, 14  13471 
 
 
The size and the surface charge of Fe3O4@heparin NP were also measured in the presence of free 
heparin (Table 5). The addition of different amounts of heparin to a solution of Fe3O4@heparin in 
water did not result in any change in its Z-A and PDI values (as determined by DLS measurements). 
Fe3O4@heparin NP maintained the highly negative surface charge as shown by ζ measurements. 
Before running the analyses, all the samples were left for 1 h to reach equilibrium. This delay could 
explain the difference of Z-A between 92 and 118 and of the PDI between 0.17 and 0.24 for the 
starting sample, see Table 3.  
Table 5. Z-A, PDI and ζ of Fe3O4@heparin (0.025 mg/mL) in the presence of different 
amounts of free heparin. 
heparin:Fe3O4@heparin (w:w) Z-A  (nm)  PDI ζ (mV) 
0:1 118  0.24  −54 
0.1:1 112  0.26  −38 
0,2:1 113  0.27  −70 
0.4:1 118  0.24  −69 
1:1 118  0.24  −73 
Fe3O4@heparin NPs were also prepared in PBS and in the presence of the surfactant Tween 20
®, as 
detailed in the experimental section. The heparin coatings are quite the same as for the Fe3O4@heparin 
NP synthesised in water (see Table 6). The PDI values are, however, much higher than those measured 
for the Fe3O4@heparin NP synthesised in water (see Table 3). The Z-A calculation makes sense only 
for the Fe3O4@heparin NP prepared in the presence of Tween 20
®. ζ values put in evidence a negative 
surface charge for all the samples. During the pre-treatment for DLS analysis, a large portion of the 
Fe3O4@heparin NP prepared in PBS was solubilised in water. The coating in PBS seems interesting as 
it could make coated NPs soluble in water.  
Table 6. Comparison of coating, size and ζ potential values of Fe3O4@heparin obtained 
under different reaction conditions. 
Reaction Conditions 
Starting NP 
(mg) 
Weight increase 
(mg) 
TB assay heparin 
coating (mg) 
Z-A  
(nm) 
PDI 
ζ Pot 
(mV) 
Water + Tween 20
®  100 5  9 93  0.25  −46 
PBS 100  6  9 -  0.38  −47 
PBS + Tween 20
® 100  8  10  -  0.32  −49 
Transmission electron microscopy (TEM) images of coated and uncoated NPs are presented in 
Figure 8. As expected, electron microscopy does not reveal any apparent differences between the 
coated and uncoated NPs (Figure 8A,B). This finding is possibly due to insufficient contrast of the 
heparin molecules with respect to the electron-dense metal NPs. The shape and dimensions of the NiO 
and Fe3O4 NPs can be observed in Figure 8C,D, respectively. The Co3O4 NP morphology appears 
quite different from the NiO and Fe3O4 NPs morphology; while the former shows globular shapes, the 
latter show much more crystalline shapes. Int. J. Mol. Sci. 2013, 14  13472 
 
 
Figure 8. Transmission electron microscopy of MO NPs. Panels A and B reveal Co3O4 
and Co3O4@heparin NPs. Panel C demonstrates the large heterogeneity in the size and 
shape of the NiO NPs. Fe3O4 NPs are shown in panel D. 
 
The formation of MO@heparin adducts has been confirmed by NMR spectroscopy. MO@heparin 
NPs described in Table 1 were analysed using 
1H High-Resolution Magic Angle Spinning (HR MAS) 
NMR (Figure 9), which combines the typical advantages of solid- and liquid-state NMR techniques, 
and, when possible, by solution NMR spectrometry (Figure 10). With the mass ratio of MO@heparin 
components being in favour of the inorganic part, the solid-state 
13C CP-MAS and MAS techniques 
were not of sufficient sensitivity to detect the polysaccharide. 
1H HR-MAS NMR spectra should, in 
principle, permit the detection of the carbohydrate connected to the particle surface [48]. 
Figure 9. 
1H HR MAS NMR comparison of the heparin spectrum with that of 
Co3O4@heparin NP. 
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Figure 10. 
1H NMR comparison of the heparin solution spectrum with that of the 
Co3O4@heparin supernatant. 
 
In our case, this detection was successful only for Co3O4@heparin NP. The lack of heparin 
detection for Fe3O4@heparin and NiO@heparin NPs can be explained by the drastic reduction of its 
mobility due to a very strong connection to the metal oxide surface. Starting from the assumption that 
the heparin NPs coating occurred in a heterogeneous phase, TEM results could be used to argue about 
HR-MAS NMR results. Figure 8 seems to suggest a relationship between the Fe3O4/NiO NPs 
morphology and the lack of heparin detection. The crystalline Fe3O4/NiO NPs could reduce the 
mobility of the coated highly charged heparin by forming ordered and rigid Fe3O4@heparin and 
NiO@heparin NPs. The interaction between the apparently amorphous Co3O4 NP and heparin could 
allow the heparin coating to maintain a certain grade of mobility.  
In Figure 9, the HR-MAS spectrum of Co3O4@heparin NP suspended in D2O is compared with that 
of heparin alone. The selective disappearance of the anomeric signal (H1) of 2-O-sulphate iduronic 
acid (I2S) residues is evident and indicates their interaction with the surface of Co3O4.  
To investigate this interaction in more detail, we used conventional NMR techniques to examine the 
supernatant of the Co3O4@heparin centrifugation isolating step, which contains some residual 
Co3O4@heparin NP and an excess of heparin (see the monodimensional 1D spectra presented in   
Figure 10). The same selective broadening of the uronic acid was observed upon introduction of 
paramagnetic species [49,50]. 
Based on the 2D heteronuclear correlation NMR spectrum of the Co3O4@heparin supernatant, the 
previous HR-MAS result was confirmed and additional details were observed (see Figures 11 and 12). 
Indeed, not only the I2S residues but also minor non-sulphated iduronic and glucuronic residues are 
involved in the interaction, indicating that all of the uronic acid residues are responsible for the 
electrostatic interaction. 
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Figure 11. 2D hetero-nuclear correlation NMR spectrum of the Co3O4@heparin supernatant. 
 
Figure 12. (Left) Expansion of the anomeric region of the 2D hetero-nuclear correlation 
NMR spectrum of the Co3O4@heparin supernatant (red) overlapped with the mother heparin 
(black); (Right) Same expansion with signal intensities increased up to the noise level. 
 
Moreover, the signal of the proton linked to the carbon bearing the sulphate residue of I2S   
is unaffected, supporting the hypothesis that the site of heparin- Co3O4 NP interaction is the   
carboxyl group.  
The influence of substitution pattern and cation binding on conformation of heparin in solution has 
been studied by NMR [51]. The I2S anomeric signal collapses because of metal ion interaction; a 
similar effect occurred for H5, the closest proton to the carboxyl moiety. For Co3O4@heparin NP, this 
phenomenon did not occur, as the unaffected I2S H5 signal remains evident in both the 1D and the 2D 
hetero-correlation spectra.  Int. J. Mol. Sci. 2013, 14  13475 
 
 
Whereas the FT-IR technique helped to visualise the MO@heparin NPs and the TB test quantified 
the heparin coating, the NMR technique investigations offered an original method of examining 
MO@heparin NPs. According to NMR technique results, we can argue that the core in Fe3O4@heparin 
and NiO@heparin NPs seems to immobilize the heparin shell, while the core in Co3O4@heparin NP 
has specific interactions with the heparin shell that anyway maintains its mobility.  
3. Experimental Section  
3.1. Synthesis of MO@heparin NPs (Core@Shell: MO@heparin).  
Fe3O4 (CAS Number 1317-61-9), Co3O4 (CAS Number 1308-06-1), and NiO (CAS Number   
1313-99-1) NPs (particle size <50 nm by TEM measurements, as described by supplier) were 
purchased from Sigma-Aldrich (St. Louis, USA) and used as received. Heparin, in the form of sodium 
salt, was provided by LDO Company (Trino Vercellese, Italy). In a general synthesis experiment, a 
suspension of NPs in distilled water (4 mg/mL) obtained by ultra-sonication for 5 min (Sonica 
5300MH-Soltec, Milan, Italy) was transferred into a solution of heparin (40 mg/mL, pH 7 adjusted 
with 0.01 N NaOH). The mixture was stirred overnight (130–150 rpm, 20–25 °C, Julabo SW22). 
Co3O4@heparin and NiO@heparin NPs were separated by centrifugation (1 h, 6300g, Hettich 
Zentrifugen-Rotina 35 F, Tuttlingen, Germany), whereas Fe3O4@heparin NP was separated using a 
magnet (Ni–Cu–Ni Nickel plated, magnetisation N45). MO@heparin NPs were exhaustively washed 
with diethyl ether and then dried in air and in a conventional oven at 50 °C for 1 h.  
Following the same reaction conditions and work up in water, Fe3O4@heparin NPs were prepared 
in a phosphate buffered saline (PBS) solution (0.137 M NaCl, 3 mM KCl, 0.01 M Na2HPO4, and  
2 mM KH2PO4), in water with 1% w/w Tween 20
® (Sigma Aldrich, St. Louis, USA) as the surfactant 
and in PBS with 1% w/w Tween 20
®. The pH value after the dissolution of heparin in PBS was 7.2.  
Fe3O4@heparin NPs were also prepared in water by changing the heparin/Fe3O4 ratio. Six milliliter 
of a 40 mg/mL solution of Fe3O4 was added, after 5 min of ultra-sonication, to different volumes of a  
40 mg/mL heparin solution at pH 7. 
3.2. IR Characterisation of MO@heparin NPs 
Heparin, the final MO@heparin NPs and the starting NPs were mixed with infrared grade KBr in a 
convenient proportion. The solid phase Fourier transform infrared (FT-IR) spectra were collected on a 
Bruker IFS 25. 
3.3. Standard Curve for the Toluidine Blue (TB) Assay 
The standard curve of TB absorbance at 633 nm was constructed at increasing concentrations of 
heparin (range 0.01 mg/mL:0.0009 mg/mL) by mixing 1 mL of TB (0.04 mg/mL), 1 mL of water and 
1 mL of different concentration heparin solutions (Figure 13). A second standard curve was obtained 
after extraction of each heparin:TB mixture with hexane. The two curves overlapped. 
  Int. J. Mol. Sci. 2013, 14  13476 
 
 
Figure 13. Standard curve showing the decrease in absorbance of a TB solution at 633 nm 
with increasing concentrations of heparin. 
 
3.4. TB Assay Heparin Content in MO@heparin NPs and IR Characterisation of  
MO@heparin-TB Adducts 
Suspensions obtained by mixing 1 mL of MO@heparin NPs or of bare NPs (0.05 mg/mL), 1 mL of 
TB (0.04 mg/mL) and 1 mL of water were stirred (30 min, 130–150 rpm, 25 °C, Julabo SW22) and 
centrifuged (20 min, 5000 rpm, 20 °C, Hettich Zentrifugen-Rotina 35 F). The supernatant TB blue 
solutions were UV analysed from 300 to 800 nm, and the absorbance at 633 nm was examined. The 
purple MO@heparin-TB adducts and the black bare NPs were dried under vacuum and investigated 
using IR, following the same procedure detailed for the MO@heparin NPs. 
3.5. NMR Characterisation of Co3O4@heparin 
The 
1H High-Resolution Magic Angle Spinning (HR MAS) NMR spectra were recorded using a 
Bruker Avance 300 WB spectrometer (Karlsruhe, Germany) equipped with a 4-mm MAS probe. The 
samples were placed in a zirconium rotor, 4 mm in diameter and 21 mm high. Wet (D2O) sample 
analysis was run at a spin rate of 2500 Hz. The measurements were performed using a cpmg1ld 
standard sequence for water signal presaturation, under the following experimental parameters: D1 3 s, 
AQ 270 ms, P90 4 µs, NS 1024, T2 loop 16 ms, using tetramethylsilane as the reference.  
Two-dimensional heteronuclear single quantum coherence (2D-HSQC) spectra were recorded at 
25 °C on a Bruker Avance 500 spectrometer (Karlsruhe, Germany) equipped with a 5-mm TCI inverse 
probe under the following experimental conditions: carbon decoupling during acquisition, 320 
increments of 32–64 scans. The polarisation transfer delay (D = 1/[2 × 
1JC–H]) was established using  
1JC–H coupling values of 150 Hz. The matrix size 1 K × 512 was zero filled to 4 K × 2 K by applying a 
squared cosine function before Fourier transformation. 
3.6. Dynamic Light Scattering (DLS) and Zeta Potential (ζ) of MO@heparin NPs and of Bare NPs 
A 0.025 mg/mL solution of MO and MO@heparin NPs in water was prepared by immersing the 
solution in an ultrasonic bath for 1–5 s followed by centrifugation (Minispin, 1 min, 5000 rpm). The 
supernatant was immediately analysed in a folded capillary cell using DLS and Zetasizer Nano ZS, 
ZEN3600 from Malvern Instruments, at 25 °C and a scattering angle of 173°. The kinetic behaviour of 
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Fe3O4@heparin in water was analysed based on DLS measurements at 37 °C using a quartz cuvette of 
1 cm optic length Zetasizer Software 6.20 was used to analyse the field autocorrelation function in 
terms of the distribution of relaxation rates. The zeta potential size was automatically calculated from 
the electrophoretic mobility based on the Henry equation, UE = 2εζf(ka)/3η, where ζ is the zeta 
potential, UE is the measured electrophoretic velocity, η is the viscosity, ε is the dielectric constant and 
f(ka) is Henry’s function (adopted value: 1.5, referring to the Smoluchowski approximation). The   
Z-Average values obtained by DLS technique were calculated by the software as the average of ten 
measurements of the same suspension, each one obtained registering ten scans. The ζ values were 
calculated by the software as the average of six measurements of the same suspension. 
The DLS and ζ measurements were also registered at increasing concentrations of free heparin by 
mixing 5 mL of Fe3O4@heparin (0.05 mg/mL) with different volumes of heparin (0.05 mg/mL) and 
adding water to reach a total volume of 10 mL. After 1 h., the solutions were centrifuged (Minispin, 
5000 rpm, 1 min), and the supernatant was analysed at 25°C. 
3.7. Transmission Electron Microscope (TEM) Characterisation of MO@heparin NPs and of  
Bare NPs 
Five microliter drops of the different NP suspensions were deposited on 400 mesh copper grids 
coated with a formvar-carbon film (Società Italiana Chimici, Roma, Italy). After a few minutes, the 
excess liquid was removed using blotting paper. The grids were allowed to air dry at room temperature 
in a clean area. The samples were analysed using a Tecnai T12 TEM (FEI, Eindhoven, The 
Netherlands) operating at 120 kV. 
4. Conclusions  
Surface functionalisation of magnetic NPs is a necessary step for their application. In light of recent 
developments in nanomedicine, heparin-coated NPs may act as precious tools for cancer theranostics 
and surface functionalisation, with heparin being of particular interest because of its many biological 
activities. In this study, Co3O4, Fe3O4 and NiO NPs were directly conjugated to heparin, producing 
ultra-stable and intact heparin-coated NPs. The method is equally suitable for the three types of 
particles, and there are no significant differences in the heparin coating efficacy. The use of different 
analytic and characterisation techniques permitted us to describe in detail the heparin coated MO NPs. 
In particular, the heparin coating reduces the agglomeration of all the MO NPs in water and makes 
their surface highly negatively charged. Heparin coated MO NPs maintain the morphology of the bare 
NPs, but differ due to heparin coating mobility. The interaction with Fe3O4 and NiO reduce heparin 
mobility while the interaction with Co3O4 maintains heparin mobility as detected by NMR experiments. 
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